Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Capital Expenditures (2017 - 2020)

VYNE Therapeutics (VYNE) has disclosed Capital Expenditures for 4 consecutive years, with $71000.0 as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Capital Expenditures fell 77.53% year-over-year to $71000.0, compared with a TTM value of $71000.0 through Mar 2021, down 92.62%, and an annual FY2024 reading of $117000.0, changed N/A over the prior year.
  • Capital Expenditures was $71000.0 for Q2 2020 at VYNE Therapeutics, up from $42000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $449000.0 in Q4 2018 and bottomed at $12000.0 in Q4 2017.
  • Average Capital Expenditures over 4 years is $204000.0, with a median of $167500.0 recorded in 2019.
  • The sharpest move saw Capital Expenditures skyrocketed 3641.67% in 2018, then plummeted 77.53% in 2020.
  • Year by year, Capital Expenditures stood at $12000.0 in 2017, then surged by 3641.67% to $449000.0 in 2018, then crashed by 56.12% to $197000.0 in 2019, then plummeted by 63.96% to $71000.0 in 2020.
  • Business Quant data shows Capital Expenditures for VYNE at $71000.0 in Q2 2020, $42000.0 in Q1 2020, and $197000.0 in Q4 2019.